Baseline renal function, weight, G-CSF use, and transplantation rate at each HDAC cycle
| . | HDAC-123, n = 92 (41.6%) . | HDAC-135, n = 129 (58.4%) . | P . |
|---|---|---|---|
| Creatinine at day 1 of each cycle, median (IQR), µM/L | |||
| Cycle 1 | 60.5 (52.5, 71.5) | 70.0 (57.0, 80.0) | .001 |
| Cycle 2 | 63.0 (55.0, 72.0) | 68.0 (58.0, 76.0) | .04 |
| Cycle 3 | 63.0 (57.0, 71.0) | 67.0 (57.0, 78.0) | .11 |
| Weight at day 1 of each cycle, median (IQR), kg | |||
| Cycle 1 | 70.6 (63.0, 81.0) | 69.5 (59.0, 82.0) | .34 |
| Cycle 2 | 73.0 (67.0, 83.0) | 71.0 (61.3, 84.0) | .23 |
| Cycle 3 | 74.0 (65.0, 85.5) | 72.0 (60.5, 82.0) | .23 |
| Prophylactic G-CSF, n (%) | |||
| Cycle 1 | <.001 | ||
| Standard G-CSF | 1 (1.1) | 48 (37.2) | |
| Pegylated G-CSF | 90 (97.8) | 81 (62.8) | |
| None | 1 (1.1) | 0 (0.0) | |
| Cycle 2 | <.001 | ||
| Standard G-CSF | 4 (5.0) | 37 (32.7) | |
| Pegylated G-CSF | 76 (95.0) | 71 (62.8) | |
| None | 0 (0.0) | 5 (4.4) | |
| Cycle 3 | <.001 | ||
| Standard G-CSF | 2 (4.3) | 25 (32.5) | |
| Pegylated G-CSF | 45 (95.7) | 51 (66.2) | |
| None | 0 (0.0) | 1 (1.3) | |
| Allogeneic SCT rate after each cycle, n (%) | .39 | ||
| Cycle 1 | 8 (8.7) | 11 (8.5) | |
| Cycle 2 | 30 (32.6) | 31 (24.0) | |
| Cycle 3 | 7 (7.6) | 7 (5.4) | |
| None | 47 (51.1) | 80 (62.0) |
| . | HDAC-123, n = 92 (41.6%) . | HDAC-135, n = 129 (58.4%) . | P . |
|---|---|---|---|
| Creatinine at day 1 of each cycle, median (IQR), µM/L | |||
| Cycle 1 | 60.5 (52.5, 71.5) | 70.0 (57.0, 80.0) | .001 |
| Cycle 2 | 63.0 (55.0, 72.0) | 68.0 (58.0, 76.0) | .04 |
| Cycle 3 | 63.0 (57.0, 71.0) | 67.0 (57.0, 78.0) | .11 |
| Weight at day 1 of each cycle, median (IQR), kg | |||
| Cycle 1 | 70.6 (63.0, 81.0) | 69.5 (59.0, 82.0) | .34 |
| Cycle 2 | 73.0 (67.0, 83.0) | 71.0 (61.3, 84.0) | .23 |
| Cycle 3 | 74.0 (65.0, 85.5) | 72.0 (60.5, 82.0) | .23 |
| Prophylactic G-CSF, n (%) | |||
| Cycle 1 | <.001 | ||
| Standard G-CSF | 1 (1.1) | 48 (37.2) | |
| Pegylated G-CSF | 90 (97.8) | 81 (62.8) | |
| None | 1 (1.1) | 0 (0.0) | |
| Cycle 2 | <.001 | ||
| Standard G-CSF | 4 (5.0) | 37 (32.7) | |
| Pegylated G-CSF | 76 (95.0) | 71 (62.8) | |
| None | 0 (0.0) | 5 (4.4) | |
| Cycle 3 | <.001 | ||
| Standard G-CSF | 2 (4.3) | 25 (32.5) | |
| Pegylated G-CSF | 45 (95.7) | 51 (66.2) | |
| None | 0 (0.0) | 1 (1.3) | |
| Allogeneic SCT rate after each cycle, n (%) | .39 | ||
| Cycle 1 | 8 (8.7) | 11 (8.5) | |
| Cycle 2 | 30 (32.6) | 31 (24.0) | |
| Cycle 3 | 7 (7.6) | 7 (5.4) | |
| None | 47 (51.1) | 80 (62.0) |